AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11528569
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin (1 g given weekly)
Trial: 11528569
Drug: Benzathine penicillin
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzathine penicillin G (1.2 million U)
Trial: 3277450
Drug: Mutual‐help group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mutual‐help group treatment led by nonclinicians
Trial: 3277450
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Brief dynamic psychotherapy and Mutual-help group treatment)
Trial: 28363636
Drug: DSM265 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSM265 (150 mg)
Trial: 28363636
Drug: Mefloquine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (10 mg/kg)
Trial: 26431662
Drug: 10mg adefovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg adefovir dipivoxil capsules once daily
Trial: 26431662
Drug: 10mg adefovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg adefovir dipivoxil capsules once daily + 5 million U Recombinant Human Interferon α‐2b every other day
Trial: 26431662
Drug: 10mg adefovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg adefovir dipivoxil capsules once daily (control group)
Trial: 19648681
Drug: CPT before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT before BiPAP treatment
Trial: 19648681
Drug: BiPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BiPAP treatment after conventional anti-infection, phlegm treatment and support treatment
Trial: 17455407
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml isotonic normal saline (Control)
Trial: 12414877
Drug: QUICKI (quantitative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QUICKI (quantitative insulin sensitivity check index)
Trial: 12414877
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance measured by HOMA
Trial: 9809097
Drug: All solutions
RxNorm normalized name: ALCOHOL 0.57 mL in 1 mL / IODINE 0.06 g in 1 mL / POTASSIUM IODIDE 0.05 g in 1 mL / BORIC ACID 0.01 g in 1 mL / SODIUM BORATE 0.002 g in 1 mL TOPICAL LINIMENT [Ball Solutions]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All solutions at 50 vol.%
Trial: 2676967
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desipramine (DMI) at an average maximal daily dose of 4.6 +/- 0.2 mg/kg
Trial: 365323
Drug: Levamisole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (50 mg three times a day)
Trial: 28675067
Drug: Neoadjuvant temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant temozolomide (NeoTMZ) 200 mg/m2 days 1-5 every 28 days followed by RT 60 Gy in 30 fractions
Trial: 22019520
Drug: TG4010 plus
RxNorm normalized name: TG4010
DrugBank: TG4010 (DB06584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG4010 plus chemotherapy (cisplatin 75 mg/m² on day 1 and gemcitabine 1250 mg/m² on days 1 and 8, repeated every 3 weeks for up to six cycles)
Trial: 22019520
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (cisplatin 75 mg/m² on day 1 and gemcitabine 1250 mg/m² on days 1 and 8, repeated every 3 weeks for up to six cycles)
Trial: 17444589
Drug: Infliximab 3
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 3 mg/kg plus MTX
Trial: 17444589
Drug: Infliximab 6
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 6 mg/kg plus MTX
Trial: 15361763
Drug: L-arginine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (10 micromol/min)
Trial: 15361763
Drug: N-monomethyl-L-arginine (L-NMMA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-monomethyl-L-arginine (L-NMMA; 4 micromol/min)
Trial: 12575372
Drug: Tracheitis Plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tracheitis Plaster (TP) applied on acupoints Dingchuan, Dashu, Fengmen, Feishu and Xinshu at back along both sides of thoracic vertebrae 1‐6, treatment duration: 20 times.
Trial: 12575372
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of Siqikang, treatment duration: 20 times.
Trial: 3549096
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray (200 units daily)
Trial: 3549096
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray (400 units daily)
Trial: 3549096
Drug: Suppository (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppository (300 units)
Trial: 3549096
Drug: Parenteral route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral route
Trial: 31509844
Drug: Calcipotriol-betamethasone ointment
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcipotriol-betamethasone ointment
Trial: 27473888
Drug: Radium-223 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radium-223 (50 kBq/kg every 4 weeks for up to six injections)
Trial: 27473888
Drug: Any-grade treatment-emergent
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any-grade treatment-emergent adverse events
Trial: 27473888
Drug: Grade 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grade 3 or worse treatment-related adverse events
Trial: 23887199
Drug: Low-volume group
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume group (1 ml·kg·h of balanced Ringer's solution until the end of cystectomy and then 3 ml·kg·h until the end of surgery combined with preemptive norepinephrine infusion at an initial rate of 2 µg·kg·h)
Trial: 23887199
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (6 ml·kg·h of balanced Ringer's solution throughout surgery)
Trial: 23327960
Drug: Arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Arsenic trioxide combined with transcatheter arterial chemoembolization (TACE) - 10 mg arsenic trioxide by intravenous infusion for 5 hours per day, 3 days after TACE, repeated every 2 weeks for 3-4 cycles
Trial: 19733912
Drug: Acute phase
RxNorm normalized name: Acute phase reactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute phase cognitive therapy (A‐CT)
Trial: 9504514
Drug: Autologous bone-marrow
RxNorm normalized name: SUS SCROFA BONE MARROW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone-marrow transplant (BMT) after preparation with cyclophosphamide and total-body irradiation
Trial: 8061425
Drug: BMS 180549
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS 180549 (superparamagnetic iron oxide contrast agent)
Trial: 2661065
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cyclosporin A (CyA)
Trial: 2661065
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cyclosporin A (CyA)
Trial: 2661065
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cyclosporin A (CyA) with NSAIDs
Trial: 780406
Drug: Specific injection
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific injection therapy
Trial: 31236286
Drug: Hyoscine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine (1 week at 0.6 mg daily, 3 weeks at 0.9 mg daily)
Trial: 31236286
Drug: Glycopyrrolate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (1 week at 2 mg daily, 3 weeks at 3 mg daily)
Trial: 29231337
Drug: Balance acupuncture
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance acupuncture at Toutongxue point, treatment for 4 weeks, once a day, 5 times a week.
Trial: 29231337
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture at a control point (3, 4 metatarsal combination), treatment for 4 weeks, once a day, 5 times a week.
Trial: 23322818
Drug: MHT (Menopausal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MHT (Menopausal Hormone Treatment)
Trial: 16404492
Drug: High-impact exercise
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-impact exercise (acceleration levels exceeding 3.9 g)
Trial: 16404492
Drug: High-impact exercise
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-impact exercise (acceleration levels exceeding 5.4 g)
Trial: 16404492
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity at levels of 1.1-2.4 g
Trial: 11244343
Drug: Hypotonic artificial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic artificial tears, administered up to 6 times a day
Trial: 11244343
Drug: Isotonic artificial
RxNorm normalized name: ISOTON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic artificial tears, administered up to 6 times a day
Trial: 9256118
Drug: MOPP-ABVD with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOPP-ABVD with low-dose total-nodal irradiation (TNI)
Trial: 9256118
Drug: MOPP-ABVD only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOPP-ABVD only (chemotherapy-only group)
Trial: 8509099
Drug: Cryotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy plus subcutaneously administered interferon alpha‐2a
Trial: 10462244
Drug: Inactivated polio
RxNorm normalized name: Inactivated polio vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated polio vaccine (IPV)
Trial: 24286534
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg Polaprezinc (PZ) enema
Trial: 12848770
Drug: Fluticasone/Salmeterol (FP/SM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/Salmeterol (FP/SM) 125 microg/SM 25 microg, 1 puff twice daily for 3 weeks
Trial: 2938688
Drug: Arginine aspartate
RxNorm normalized name: Arginine aspartate
DrugBank: Arginine aspartate (DB15993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arginine aspartate 37.5 g
Trial: 29530622
Drug: Capsaicin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin (2 mg)
Trial: 23054576
Drug: Bioenterics Intragastric
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAGASTRIC LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioenterics Intragastric Balloon (BIB) - saline-filled (500 ml saline + 10 ml methylene blue)
Trial: 23054576
Drug: Endobag-Heliosphere -
RxNorm normalized name: Fluzone 2025 Southern Hemisphere
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endobag-Heliosphere - air-filled (950 ml air)
Trial: 19855926
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg ibandronate given intravenously once every 3 months
Trial: 19855926
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg alendronate given orally once per week
Trial: 15251160
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg ibandronate
Trial: 19855926
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg alendronate
Trial: 15339678
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) 9 mg/m2 infused intravenously on days 1 and 15 followed by conventional chemotherapy (MICE regimen: mitoxantrone, cytarabine, etoposide)
Trial: 10791297
Drug: Metrifonate (MTF)
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate (MTF) 2.9 mg/kg weekly for 6 months
Trial: 10791297
Drug: Metrifonate (MTF)
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate (MTF) daily to achieve RBC AChE inhibition levels of 85.90%
Trial: 8449581
Drug: Recombinant HB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant HB vaccine (Engerix‐B, 20 micrograms) given to 40 susceptible health-care workers within three days of exposure (Group B)
Trial: 8449581
Drug: A single
RxNorm normalized name: Hemoccult Sensa Single Slide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of HBIg (0.06 mg/kg) administered intramuscularly within three days of exposure followed by the first dose of vaccine (20 micrograms) (Group A)
Trial: 3092933
Drug: Acupuncture after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture after premedication with 100 mg meptazinol (first study)
Trial: 3092933
Drug: Acupuncture with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture with 10 mg nalbuphine (second study)
Trial: 25866234
Drug: EtG immunoassay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EtG immunoassay cutoff levels at 100 ng/ml
Trial: 25866234
Drug: EtG immunoassay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EtG immunoassay cutoff levels at 200 ng/ml
Trial: 25866234
Drug: EtG immunoassay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EtG immunoassay cutoff levels at 300 ng/ml
Trial: 25866234
Drug: EtG immunoassay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EtG immunoassay cutoff levels at 400 ng/ml
Trial: 25866234
Drug: EtG immunoassay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EtG immunoassay cutoff levels at 500 ng/ml
Trial: 22936539
Drug: Four weekly
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four weekly multiprofessional senior group meetings including a follow-up home visit
Trial: 21705273
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch (titrated from 0.5 mg/24 h to a maximum of 4 mg/24 h)
Trial: 25773763
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch (4 mg/24 h)
Trial: 21705273
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch (1-3 mg/24 h)
Trial: 19508310
Drug: Moisturizer (urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moisturizer (urea containing), applied twice daily during a 26-week maintenance phase
Trial: 19508310
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (untreated areas)
Trial: 12542609
Drug: GenHevac B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GenHevac B vaccine (3 standard injections at 0, 30, and 60 days)
Trial: 12690275
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no medication or vaccination)
Trial: 9379571
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution flush (3 ml)
Trial: 9379571
Drug: Heparin solution
RxNorm normalized name: heparin Injectable Solution
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin solution flush (3 ml of 10 units heparin/ml normal saline)
Trial: 9379571
Drug: Cost-saving implications
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cost-saving implications of normal saline solution
Trial: 8405007
Drug: Oxcarbazepine 150
RxNorm normalized name: oxcarbazepine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine 150 mg b.i.d.
Trial: 8405007
Drug: Oxcarbazepine 300
RxNorm normalized name: oxcarbazepine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine 300 mg b.i.d.
Trial: 3485119
Drug: Chewable aspirin
RxNorm normalized name: ASPIRIN 81 mg ORAL TABLET, CHEWABLE [Chewable Aspirin]
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chewable aspirin (10-15 mg/kg)
Trial: 3485119
Drug: Acetaminophen (10-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (10-15 mg/kg)
Trial: 31380003
Drug: Aggressive fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive fluid therapy with 20 mL/kg of ringer lactate infusion within 90 minutes before ERCP and 3 mL/kg/h during ERCP followed by 3 mL/kg/h up to 8 hours
Trial: 31380003
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 1.5 mL/kg of ringer lactate infusion during ERCP up to 8 hours later
Trial: 21146749
Drug: HGF gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HGF gene therapy
Trial: 20689464
Drug: Tibolone 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 1.25 mg/day
Trial: 17613583
Drug: Calcium/vitamin D
RxNorm normalized name: CALCIUM/VITAMIN D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium/vitamin D supplements
Trial: 9565804
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) - 150 mg/kg bolus in 250 ml of 5% dextrose followed by continuous infusion of 12 mg/kg per hour in 500 ml of 5% dextrose over 24 hours for a minimum of 3 days up to a maximum of 5 days.
Trial: 9565804
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - equal volume of placebo administered for the same duration as NAC.
Trial: 3357653
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (E2) patch 50 micrograms/day
Trial: 28768538
Drug: Pulsed radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed radiofrequency (PRF) treatment
Trial: 26201713
Drug: Rifaximin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin (400 mg thrice a day)
Trial: 26201713
Drug: Lactulose (30-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (30-120 ml/day)
Trial: 21748313
Drug: Oral fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluids only
Trial: 21748313
Drug: Intravenous Ringer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Ringer lactate at 125 ml/h
Trial: 21748313
Drug: Intravenous Ringer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Ringer lactate at 250 ml/h
Trial: 17634541
Drug: High levels
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High levels of IFN gamma receptor
Trial: 17634541
Drug: Complete loss
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete loss of IFN gamma receptor
Trial: 10917002
Drug: 2.5 mEq/l
RxNorm normalized name: bicarb dialy soln 11 without K calcium (2.5 mEq/L)-magnesium (1.5 mEq/L) HEMODIALYS SOLUTION, NON-ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mEq/l dialysate calcium (DCa)
Trial: 10917002
Drug: 3 mEq/l
RxNorm normalized name: physiological irrig soln no.1 140 mEq-5 mEq-3 mEq-98 mEq-27 mEq-23 mEq/L IRRIGATION SOLUTION, IRRIGATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mEq/l dialysate calcium (DCa)
Trial: 2056888
Drug: L-sulpiride (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-sulpiride (150 mg po/die)
Trial: 2056888
Drug: Racemic sulpiride
RxNorm normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic sulpiride (300 mg po/die)
Trial: 6318655
Drug: Intranasal human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal human interferon alpha A
Trial: 27094556
Drug: brush‐plus‐rinse treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brush‐plus‐rinse treatment
Trial: 27094556
Drug: brush‐alone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brush‐alone treatment
Trial: 17848748
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: zoledronic acid (4 mg, iv, every 28 d)
Trial: 9061712
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity assessment using the Bergman minimal model
Trial: 9061712
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity at 12 months
Trial: 8141692
Drug: Captopril (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (6.25 mg twice daily)
Trial: 7881704
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg once daily)
Trial: 3533455
Drug: Intravenous theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous theophylline (100 mg)